Stigma of opioid addiction barrier to improving care

By
-
INCREASED COMPETITION: Dr. Jason Spangler, foreground, executive director of medical policy and quality strategies for Amgen, speaks during the Oct. 5 PBN Health Care Summit about how Amgen is working to lower prescription drug costs by increasing competition. / PBN PHOTO/RUPERT WHITELEY
INCREASED COMPETITION: Dr. Jason Spangler, foreground, executive director of medical policy and quality strategies for Amgen, speaks during the Oct. 5 PBN Health Care Summit about how Amgen is working to lower prescription drug costs by increasing competition. / PBN PHOTO/RUPERT WHITELEY
The stigma surrounding the opioid addiction is similar to that of the AIDS epidemic in recent decades, says Dr. Martin Serota, chief medical officer for Prospect Charter­Care Health Partners. The AIDS crisis became much more manageable with the cooperation of doctors, researchers and the pharmaceutical industry, he said. “We need to do the same thing…

You must be a subscriber to read this content. To keep reading and receive unlimited access subscribe today for only $1.
Subscribe Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

RELATED ARTICLESMORE FROM AUTHOR

No posts to display